February 21, 2026
Headlines

Candel Therapeutics Stock Surges Over 100% – Here’s Why

01 mins

Candel Therapeutics reports phase 3 trial success for CAN-2409 in prostate cancer, showing improved disease-free survival and safety consistency.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *

Related News